Back to List View Graph View

DNA topoisomerase I

Topoisomerase 1 Dmel_CG6146 is the Drosophila melanogaster ortholog of human DNA topoisomerase I (TOP1), encoded by CG6146. topoisomerase I resolves the topological strain that accumulates ahead of replication forks and transcribing polymerases: it cleaves one strand of the duplex, forming a transient covalent intermediate — the TOP1 cleavage complex (TOP1cc), in which an active-site tyrosine is linked to the 3′ end of the nick — allows the DNA to rotate about the intact strand, and then reseals it.

Where the papers sit

12 papers from the last 6 months study DNA topoisomerase I directly · updated from PubMed 15 Nov 2026

Study type 0 clinical trials · 1 observational · 9 preclinical · 2 unclassified

Themes 3 themes · 1 new direction

  • Next-Generation TOP1 Therapies

    TOP1 therapy is moving beyond conventional camptothecins toward dual inhibitors, degraders, antibody-drug conjugates and supramolecular delivery systems. PARP1 inhibition, CDK7 blockade and hydrophobic tagging are used to increase tumor sensitivity or convert camptothecin into a degrader. Bioorthogonal release and phospholipid nanotubes seek better tumor delivery, while linker hydrolysis and lactone-ring opening complicate drug-to-antibody ratio measurement. The direction is combination and formulation optimization, but benefit remains largely preclinical.

    6 papers · 50%

  • Breast Cancer Therapeutics

    TROP2 antibody-drug conjugates are being evaluated alongside mechanistic work linking inflammation to breast cancer progression. Safety management, particularly interstitial lung disease, is a prominent concern for anti-TROP2 ADCs. Thrombin-PAR1 signaling connects inflammatory cues to Topoisomerase 1 activity, suggesting a route to understand tumor behavior rather than a validated treatment. Pharmacogenomics and AI may support risk stratification, but no common therapeutic direction is established.

    2 papers · 16.7%

  • Others — Cancer Drugs and Jaw Surgery

    Camptothecin and selenium–matrine hybrids are being explored as TOP1-targeted anticancer agents, with potency and apoptosis as recurring endpoints. Hydroxycamptothecin design uses molecular dynamics, while A10 formulation work targets oral bioavailability and cGAS-STING/ICD activation in bladder cancer. A separate mandibular AOT report concerns combined treatment and bone healing, not TOP1 biology. No single translational direction unites the cluster.

    4 papers · 33.3%

NEW DIRECTION

Thrombin–PAR1 signaling positions DNA topoisomerase I as an inflammatory signaling effector rather than only a DNA-damage target

The thrombin–PAR1 signaling model in triple-negative breast cancer found that thrombin increased Top1 activity without changing its expression, thereby amplifying NF-κB-dependent cytokine production through Par-4 suppression 42219057May. This departs from the set’s predominant use of DNA topoisomerase I as a pharmacological target or cytotoxic payload that produces DNA damage: Top1 instead functions downstream of coagulation signaling to connect the tumor microenvironment with inflammatory transcription. As a result, Top1 activity becomes a potential mechanistic link—and intervention point—for thrombin-driven inflammation and breast-cancer progression, not merely a means of killing tumor cells.

Papers

The 12 papers from the last 6 months that study DNA topoisomerase I directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Next-Generation TOP1 Therapies (6)
  1. Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition. Science advances · 30 Sept 2026 PMID 42814835
  2. Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors. Journal of medicinal chemistry · 27 Jul 2026 PMID 42504569
  3. Surface-Confinement Effect Enables Bioorthogonal Drug Release in Tumors. Journal of the American Chemical Society · 17 Jul 2026 PMID 42468144
  4. A phospholipid Camptothecin-Niraparib conjugate self-assembled into supramolecular nanotubes for combination cancer therapy. Journal of controlled release : official journal of the Controlled Release Society · 15 Jul 2026 PMID 42456976
  5. Reprogramming Aromatic Camptothecins into TOP1 Degraders via Synergistic Hydrophobic Tagging and Supramolecular Assembly. Journal of the American Chemical Society · 30 Jun 2026 PMID 42378337
  6. A Case Study on the Impact of Thermal Hydrolysis and Lactone Ring Opening of Linker-Payload on Drug-to-Antibody Ratio Determination in a Topoisomerase I Inhibitor-Based ADC. Bioconjugate chemistry · 4 Jun 2026 PMID 42237689
Breast Cancer Therapeutics (2)
  1. Safety management of anti TROP2 ADCs in patients with breast cancer. Current opinion in oncology · 18 Sept 2026 PMID 42757501
  2. Thrombin-PAR1 signaling regulates Topoisomerase 1 activity to bridge inflammation and breast cancer progression. Cancer letters · 31 May 2026 PMID 42219057
Others — Cancer Drugs and Jaw Surgery (4)
  1. Management of mandibular AOT: outcomes following combined treatment protocol. BMJ case reports · 24 Sept 2026 PMID 42785786
  2. Discovery of novel hydroxycamptothecin derivatives as potent Topo I inhibitors for antitumor guided by molecular dynamics. European journal of medicinal chemistry · 24 Jul 2026 PMID 42497470
  3. Soluplus®-based solid dispersion enhances oral bioavailability of A10: a cGAS-STING and ICD activator for bladder cancer therapy. International journal of pharmaceutics · 12 Jul 2026 PMID 42437626
  4. Design, synthesis, and biological evaluation of novel selenium-matrine hybrid compounds as topo I -targeted anticancer agents. Bioorganic chemistry · 4 Jul 2026 PMID 42401165

By study type

Observational studies and case reports (1)
  1. Management of mandibular AOT: outcomes following combined treatment protocol. BMJ case reports · 24 Sept 2026 PMID 42785786
Preclinical: animal, cell and lab studies (9)
  1. Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition. Science advances · 30 Sept 2026 PMID 42814835
  2. Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors. Journal of medicinal chemistry · 27 Jul 2026 PMID 42504569
  3. Discovery of novel hydroxycamptothecin derivatives as potent Topo I inhibitors for antitumor guided by molecular dynamics. European journal of medicinal chemistry · 24 Jul 2026 PMID 42497470
  4. Surface-Confinement Effect Enables Bioorthogonal Drug Release in Tumors. Journal of the American Chemical Society · 17 Jul 2026 PMID 42468144
  5. A phospholipid Camptothecin-Niraparib conjugate self-assembled into supramolecular nanotubes for combination cancer therapy. Journal of controlled release : official journal of the Controlled Release Society · 15 Jul 2026 PMID 42456976
  6. Soluplus®-based solid dispersion enhances oral bioavailability of A10: a cGAS-STING and ICD activator for bladder cancer therapy. International journal of pharmaceutics · 12 Jul 2026 PMID 42437626
  7. Design, synthesis, and biological evaluation of novel selenium-matrine hybrid compounds as topo I -targeted anticancer agents. Bioorganic chemistry · 4 Jul 2026 PMID 42401165
  8. A Case Study on the Impact of Thermal Hydrolysis and Lactone Ring Opening of Linker-Payload on Drug-to-Antibody Ratio Determination in a Topoisomerase I Inhibitor-Based ADC. Bioconjugate chemistry · 4 Jun 2026 PMID 42237689
  9. Thrombin-PAR1 signaling regulates Topoisomerase 1 activity to bridge inflammation and breast cancer progression. Cancer letters · 31 May 2026 PMID 42219057
Unclassified: not yet indexed with MeSH (2)
  1. Safety management of anti TROP2 ADCs in patients with breast cancer. Current opinion in oncology · 18 Sept 2026 PMID 42757501
  2. Reprogramming Aromatic Camptothecins into TOP1 Degraders via Synergistic Hydrophobic Tagging and Supramolecular Assembly. Journal of the American Chemical Society · 30 Jun 2026 PMID 42378337